{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:12:30Z","timestamp":1792156350624,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00745-7","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:32:30Z","timestamp":1749461550000},"page":"1705-1727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0886-1707","authenticated-orcid":false,"given":"Deborah A.","family":"Nichols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9564-0901","authenticated-orcid":false,"given":"Teresa L.","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-5896","authenticated-orcid":false,"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Todd","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3186-8602","authenticated-orcid":false,"given":"Emily C.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-5654","authenticated-orcid":false,"given":"David T.","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"745_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101709","volume":"66","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Bogan RK, Arnulf I, Scammell TE, St Louis EK, Thorpy MJ. Clinical considerations for the diagnosis of idiopathic hypersomnia. Sleep Med Rev. 2022;66: 101709.","journal-title":"Sleep Med Rev"},{"key":"745_CR2","volume-title":"International classification of sleep disorders\u2014third edition, text revision","author":"American Academy of Sleep Medicine","year":"2023","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders\u2014third edition, text revision. Darien: American Academy of Sleep Medicine; 2023."},{"issue":"8","key":"745_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.5664\/jcsm.8482","volume":"16","author":"J Acquavella","year":"2020","unstructured":"Acquavella J, Mehra R, Bron M, Suomi JMH, Hess GP. Prevalence of narcolepsy, other sleep disorders, and diagnostic tests from 2013\u20132016: insured patients actively seeking care. J Clin Sleep Med. 2020;16(8):1255\u201363.","journal-title":"J Clin Sleep Med"},{"issue":"suppl 1","key":"745_CR4","doi-asserted-by":"publisher","first-page":"A369","DOI":"10.1093\/sleep\/zsad077.0838","volume":"46","author":"R Saad","year":"2023","unstructured":"Saad R, Black J, Bogan R, et al. Diagnosed prevalence of idiopathic hypersomnia among adults in the United States [abstract 0838]. Sleep. 2023;46(suppl 1):A369.","journal-title":"Sleep"},{"issue":"2","key":"745_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207994","volume":"102","author":"DT Plante","year":"2024","unstructured":"Plante DT, Hagen EW, Barnet JH, Mignot E, Peppard PE. Prevalence and course of idiopathic hypersomnia in the Wisconsin Sleep Cohort study. Neurology. 2024;102(2): e207994.","journal-title":"Neurology"},{"key":"745_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sleep.2024.11.034","volume":"126","author":"H Kadotani","year":"2025","unstructured":"Kadotani H, Matsuo M, Tran L, et al. Epidemiology of narcolepsy and idiopathic hypersomnia in Japan: a retrospective analysis of health insurance claims from the Japan Medical Data Center. Sleep Med. 2025;126:25\u201331.","journal-title":"Sleep Med"},{"key":"745_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepx.2023.100095","volume":"6","author":"MM Ohayon","year":"2023","unstructured":"Ohayon MM, Duhoux S, Grieco J, C\u00f4t\u00e9 ML. Prevalence and incidence of narcolepsy symptoms in the US general population. Sleep Med X. 2023;6: 100095.","journal-title":"Sleep Med X"},{"issue":"12","key":"745_CR8","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1212\/WNL.58.12.1826","volume":"58","author":"MM Ohayon","year":"2002","unstructured":"Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58(12):1826\u201333.","journal-title":"Neurology"},{"issue":"2","key":"745_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14011","volume":"33","author":"K \u0160onka","year":"2023","unstructured":"\u0160onka K, Feketeov\u00e1 E, Nev\u0161\u00edmalov\u00e1 S, et al. Idiopathic hypersomnia years after the diagnosis. J Sleep Res. 2023;33(2): e14011.","journal-title":"J Sleep Res"},{"key":"745_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.smrv.2016.08.005","volume":"35","author":"LM Trotti","year":"2017","unstructured":"Trotti LM. Waking up is the hardest thing I do all day: sleep inertia and sleep drunkenness. Sleep Med Rev. 2017;35:76\u201384.","journal-title":"Sleep Med Rev"},{"issue":"5","key":"745_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.5664\/jcsm.8344","volume":"16","author":"MG Miglis","year":"2020","unstructured":"Miglis MG, Schneider L, Kim P, Cheung J, Trotti LM. Frequency and severity of autonomic symptoms in idiopathic hypersomnia. J Clin Sleep Med. 2020;16(5):749\u201356.","journal-title":"J Clin Sleep Med"},{"key":"745_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/NSS.S396641","volume":"15","author":"J Stevens","year":"2023","unstructured":"Stevens J, Schneider LD, Husain A, et al. Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:593\u2013606.","journal-title":"Nat Sci Sleep"},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.sleep.2020.10.014","volume":"76","author":"HB Wasling","year":"2020","unstructured":"Wasling HB, Bornstein A, Wasling P. Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study. Sleep Med. 2020;76:104\u201312.","journal-title":"Sleep Med"},{"issue":"2","key":"745_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.sleep.2011.07.014","volume":"13","author":"A Ozaki","year":"2012","unstructured":"Ozaki A, Inoue Y, Hayashida K, et al. Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-na\u00efve patients and the general Japanese population. Sleep Med. 2012;13(2):200\u20136.","journal-title":"Sleep Med"},{"issue":"15","key":"745_CR15","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1212\/WNL.0000000000007264","volume":"92","author":"Y Dauvilliers","year":"2019","unstructured":"Dauvilliers Y, Evangelista E, Barateau L, et al. Measurement of symptoms in idiopathic hypersomnia: the Idiopathic Hypersomnia Severity Scale. Neurology. 2019;92(15):e1754\u201362.","journal-title":"Neurology"},{"issue":"2","key":"745_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5664\/jcsm.9682","volume":"18","author":"AL Rassu","year":"2022","unstructured":"Rassu AL, Evangelista E, Barateau L, et al. Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. J Clin Sleep Med. 2022;18(2):617\u201329.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"745_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2869.2010.00824.x","volume":"19","author":"C Vernet","year":"2010","unstructured":"Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res. 2010;19(4):525\u201334.","journal-title":"J Sleep Res"},{"issue":"1","key":"745_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/sleepadvances\/zpae059","volume":"5","author":"T Boulanger","year":"2024","unstructured":"Boulanger T, Pigeon P, Crawford S. Diagnostic challenges and burden of idiopathic hypersomnia: a systematic literature review. Sleep Adv. 2024;5(1): zpae059.","journal-title":"Sleep Adv."},{"issue":"6","key":"745_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5664\/jcsm.27352","volume":"4","author":"A Ozaki","year":"2008","unstructured":"Ozaki A, Inoue Y, Nakajima T, et al. Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med. 2008;4(6):572\u20138.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"745_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5664\/jcsm.5594","volume":"12","author":"NM Flores","year":"2016","unstructured":"Flores NM, Villa KF, Black J, Chervin RD, Witt EA. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12(3):401\u20137.","journal-title":"J Clin Sleep Med"},{"issue":"9","key":"745_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955\u201365.","journal-title":"J Clin Sleep Med"},{"issue":"10","key":"745_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa066","volume":"43","author":"K Maski","year":"2020","unstructured":"Maski K, Pizza F, Liu S, et al. Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1. Sleep. 2020;43(10): zsaa066.","journal-title":"Sleep"},{"issue":"1","key":"745_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5664\/jcsm.9638","volume":"18","author":"K Maski","year":"2022","unstructured":"Maski K, Mignot E, Plazzi G, Dauvilliers Y. Disrupted nighttime sleep and sleep instability in narcolepsy. J Clin Sleep Med. 2022;18(1):289\u2013304.","journal-title":"J Clin Sleep Med"},{"key":"745_CR24","doi-asserted-by":"publisher","first-page":"1107632","DOI":"10.3389\/fneur.2023.1107632","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sun Q, Tang Q, et al. Progress of autonomic disturbances in narcolepsy type 1. Front Neurol. 2023;14:1107632.","journal-title":"Front Neurol"},{"key":"745_CR25","volume-title":"International classification of sleep disorders\u2014third edition","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders\u2014third edition. Darien: American Academy of Sleep Medicine; 2014."},{"key":"745_CR26","unstructured":"Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]. Palo Alto: Jazz Pharmaceuticals, Inc.; 2023."},{"issue":"19","key":"745_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJM199511093331917","volume":"333","author":"A Szarfman","year":"1995","unstructured":"Szarfman A, Kuchenberg T, Soreth J, Lajmanovich S. Declaring the sodium content of drug products. N Engl J Med. 1995;333(19):1291.","journal-title":"N Engl J Med"},{"key":"745_CR28","unstructured":"US Food and Drug Administration. Clinical review for Binosto, NDA 202344: US Food and Drug Administration; 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202344Orig1s000MedR.pdf. Accessed Feb. 28, 2023."},{"key":"745_CR29","unstructured":"US Food and Drug Administration. Quantitative labeling of sodium, potassium, and phosphorus for human over-the-counter and prescription drug products. Guidance for industry Silver Spring, MD: USFood and Drug Administration; 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug. Accessed Oct. 11, 2022."},{"issue":"1","key":"745_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1474-4422(21)00368-9","volume":"21","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022;21(1):53\u201365.","journal-title":"Lancet Neurol"},{"issue":"3","key":"745_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa206","volume":"44","author":"RK Bogan","year":"2021","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3): zsaa206.","journal-title":"Sleep"},{"key":"745_CR32","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/NSS.S369122","volume":"14","author":"MJ Thorpy","year":"2022","unstructured":"Thorpy MJ, Arnulf I, Foldvary-Schaefer N, et al. Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia. Nat Sci Sleep. 2022;14:1901\u201317.","journal-title":"Nat Sci Sleep"},{"key":"745_CR33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Publishing; 2013.","edition":"5"},{"key":"745_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.sleep.2017.07.030","volume":"40","author":"Y Dauvilliers","year":"2017","unstructured":"Dauvilliers Y, Roth T, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med. 2017;40:53\u20137.","journal-title":"Sleep Med"},{"issue":"8","key":"745_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.sleep.2009.05.004","volume":"10","author":"J Black","year":"2009","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10(8):829\u201335.","journal-title":"Sleep Med"},{"issue":"4","key":"745_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/jsr.12468","volume":"26","author":"T Roth","year":"2017","unstructured":"Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2017;26(4):407\u201314.","journal-title":"J Sleep Res"},{"issue":"6","key":"745_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5664\/jcsm.27994","volume":"6","author":"J Black","year":"2010","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6(6):596\u2013602.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"745_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jsmc.2019.05.007","volume":"14","author":"I Arnulf","year":"2019","unstructured":"Arnulf I, Leu-Semenescu S, Dodet P. Precision medicine for idiopathic hypersomnia. Sleep Med Clin. 2019;14(3):333\u201350.","journal-title":"Sleep Med Clin"},{"issue":"5","key":"745_CR39","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.5664\/jcsm.9884","volume":"18","author":"LM Trotti","year":"2022","unstructured":"Trotti LM, Saini P, Bremer E, et al. The Psychomotor Vigilance Test as a measure of alertness and sleep inertia in people with central disorders of hypersomnolence. J Clin Sleep Med. 2022;18(5):1395\u2013403.","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"745_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab220","volume":"45","author":"E Evangelista","year":"2022","unstructured":"Evangelista E, Rassu AL, Lopez R, et al. Sleep inertia measurement with the Psychomotor Vigilance Task in idiopathic hypersomnia. Sleep. 2022;45(1): zsab220.","journal-title":"Sleep"},{"key":"745_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/NSS.S386021","volume":"15","author":"LD Schneider","year":"2023","unstructured":"Schneider LD, Stevens J, Husain AM, et al. Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:89\u2013101.","journal-title":"Nat Sci Sleep"},{"issue":"3","key":"745_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40120-024-00607-8","volume":"13","author":"AM Morse","year":"2024","unstructured":"Morse AM, Bogan RK, Roy A, Thorpy MJ. Dosing optimization of low-sodium oxybate in narcolepsy and idiopathic hypersomnia in adults: consensus recommendations. Neurol Ther. 2024;13(3):785\u2013807.","journal-title":"Neurol Ther"},{"key":"745_CR43","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.sleep.2023.11.022","volume":"113","author":"AM Husain","year":"2024","unstructured":"Husain AM, Zee PC, Leary EB, et al. Dosing and transition characteristics in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: data from the real-world TENOR study. Sleep Med. 2024;113:328\u201337.","journal-title":"Sleep Med"},{"issue":"9","key":"745_CR44","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.5664\/jcsm.11182","volume":"20","author":"W Macfadden","year":"2024","unstructured":"Macfadden W, Leary EB, Fuller DS, Kirby MT, Roy A. Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the SEGUE study. J Clin Sleep Med. 2024;20(9):1467\u201377.","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"745_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa044","volume":"43","author":"R Fronczek","year":"2020","unstructured":"Fronczek R, Arnulf I, Baumann CR, Maski K, Pizza F, Trotti LM. To split or to lump? Classifying the central disorders of hypersomnolence. Sleep. 2020;43(8): zsaa044.","journal-title":"Sleep"},{"key":"745_CR46","unstructured":"US Centers for Medicare & Medicaid Services. CPAP for obstructive sleep apnea: US Centers for Medicare & Medicaid Services; 2023. https:\/\/www.cms.gov\/medicare\/coverage\/evidence\/cpap. Accessed Nov. 27, 2023."},{"key":"745_CR47","unstructured":"Berry RB, Quan SF, Abreu AR, et al. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, version 3. Darien: American Academy of Sleep Medicine; 2023 Jan. 2020."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00745-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:42:38Z","timestamp":1757187758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00745-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00745-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Deborah A. Nichols, Douglas S. Fuller, M. Todd Kirby, Marisa Whalen, Jessica K. Alexander, and Sarah Akerman are full-time employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. Teresa L. Steininger is a former full-time employee and current contract worker for Jazz Pharmaceuticals who has received shares of Jazz Pharmaceuticals, plc. Emily C. Barker has worked as an independent contractor and advisory board member for Jazz Pharmaceuticals and has received speaker honoraria from Jazz Pharmaceuticals. David T. Plante is a consultant and advisory board member for Jazz Pharmaceuticals. He has also served as a consultant\/advisory board member for Alkermes, Harmony Biosciences, Centessa, and Takeda and a consultant for Aditum Bio, LLC, and Teva Pharmaceuticals (Australia).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"DUET is conducted in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences Ethical Guidelines, as well as applicable International Council of Harmonisation (ICH) Good Clinical Practice guidelines and applicable laws and regulations. Investigators obtain documented consent from all participants or their legal representative before participation in DUET. Informed consent forms meeting the requirements of 21 Code of Federal Regulations 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act requirements (where applicable), Regulation (EU) 2016\/679 General Data Protection Regulation requirements (where applicable), and the institutional review board\/independent ethics committee or study site are signed by participants or their legal representatives and investigator or medically qualified designee and placed in participants\u2019 medical records; a copy is also provided to participants or their legal representative. As per Advarra policy, engagement does not necessarily involve efforts to enroll people in studies; rather, it may consist in consulting with patient groups about such things as research priorities and study design and such activities do not typically require IRB review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}